Radiotherapy Department, Lyon-Sud Hospital, Pierre-Bénite, France.
Thorac Surg Clin. 2011 Feb;21(1):99-105, vii. doi: 10.1016/j.thorsurg.2010.08.011.
Radiotherapy is a major therapeutic modality for thymic malignancies. The exact role of adjuvant radiotherapy after complete resection is still debated for stage II through III tumors. Histology or size, capsular invasion, and even molecular data may be included in the decision making. Radiotherapy may be recommended for stage III thymomas, thymic carcinoma, or after incomplete surgical resection. Combination with chemotherapy may be useful, and must be further evaluated using validated end points, including 5- and 10-year time-to-progression and overall survival. Several initiatives have been taken worldwide to launch collaborative studies in the field, including prospective trials specifically readdressing the role of radiotherapy for thymic malignancies.
放射治疗是胸腺癌的主要治疗方式。对于 II 期至 III 期肿瘤,完全切除后辅助放射治疗的确切作用仍存在争议。决策中可能包括组织学或大小、包膜侵犯,甚至分子数据。放射治疗可能适用于 III 期胸腺瘤、胸腺癌或不完全手术切除后。联合化疗可能是有用的,并且必须使用经过验证的终点进一步评估,包括 5 年和 10 年的无进展时间和总生存期。全球已经采取了几项举措来开展该领域的合作研究,包括专门重新评估放射治疗胸腺癌作用的前瞻性试验。